Solid lipid formulation for neurodegenerative disorder, comprises metformin, berberine extract, stearic acid, Copolymer of polyethylene oxide and polypropylene oxide, Polyoxyethylene sorbitan monooleate, sesame oil, where it is prepared encapsulating metformin and berberine by ultrasonication,
	KUMAR A; SHARMA A K; MANI R J; YADAV R; KATARE D P
	2023-09-18
专利权人	UNIV AMITY (UAMI-C)
申请日期	2023-09-18
专利号	IN202311062576-A
成果简介	NOVELTY - Solid lipid formulation comprises 10-20 wt.% metformin hydrochloride, 5-15 wt.% berberine extract, 40-60 wt.% stearic acid as a lipid, 2-5 wt.% Poloxamer 407(RTM: Copolymer consisting of polyethylene oxide (PEO) and polypropylene oxide (PPO) blocks) as a surfactant, 1-3 wt.% Polysorbate 80(RTM: Polyoxyethylene (20) sorbitan monooleate) as a secondary surfactant, 5-10 wt.% sesame oil, where the formulation is prepared using a hot homogenization and ultrasonication method, encapsulating metformin and berberine within a lipid matrix for providing sustained release and enhanced bioavailability across the blood-brain barrier. USE - Solid lipid formulation used for treating neurodegenerative disorders (claimed) such as Alzheimer's disease or Parkinson disease, reducing oxidative stress, inflammation, neuronal apoptosis and the adverse effects of hyperglycemia for mitigating the effects of neurodegenerative diseases. No biological data given. ADVANTAGE - The solid lipid formulation is novel exhibiting synergistic action, achieves an entrapment efficiency in the range of 85-95% for metformin and berberine, optimized for controlled drug release, providing a sustained release of metformin and berberine over a period of 12-18 hours, lipid matrix enhances the stability and bioavailability of the active ingredients when administered for the treatment of neurodegenerative disorders such as Alzheimers disease or Parkinson disease, exhibit a zeta potential in the range of -20 to -30 mV, indicating stability of the lipid matrix, ensures enhanced stability, improved bioavailability, and controlled release, facilitates controlled drug release, effectively cross the bloodbrain barrier, maximizing the therapeutic potential of metformin and berberine, ensures encapsulating bioactive compounds efficiently within the lipid matrix, resulting in a product with sustained release over extended periods. DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method for preparing a solid lipid formulation, comprising: (a) mixing metformin hydrochloride and berberine extract with stearic acid, Poloxamer 407, Polysorbate 80, and sesame oil; (b) homogenizing the mixture at a temperature range of 50-60℃ at a speed of 20,000-25,000 revolutions per minute for 5-10 minutes; (c) subjecting the homogenized mixture to ultrasonication for 20-30 minutes, and (d) allowing the resultant mixture to stand at room temperature for 24 hours.
IPC 分类号	A61K-031/155 ; A61K-031/4375 ; A61K-009/20 ; A61P-025/00 ; A61P-025/28
国家	印度
专业领域	医药卫生
语种	英语
成果类型	专利
文献类型	科技成果
条目标识符	http://119.78.100.226:8889/handle/3KE4DYBR/20361
专题	中国科学院新疆生态与地理研究所
作者单位	UNIV AMITY (UAMI-C)
推荐引用方式 GB/T 7714	KUMAR A,SHARMA A K,MANI R J,et al. Solid lipid formulation for neurodegenerative disorder, comprises metformin, berberine extract, stearic acid, Copolymer of polyethylene oxide and polypropylene oxide, Polyoxyethylene sorbitan monooleate, sesame oil, where it is prepared encapsulating metformin and berberine by ultrasonication,. IN202311062576-A[P]. 2023.

条目包含的文件
条目无相关文件。

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。